Pyruvate Dehydrogenase antibody | knockout validation | Cell Signaling 3205

This is a knockout-validated antibody summary, based on the publication "Pyruvate dehydrogenase expression is negatively associated with cell stemness and worse clinical outcome in prostate cancers", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Pyruvate Dehydrogenase antibody | knockout validation | Cell Signaling 3205 figure 1
Figure 1. The expressions of PDHA1 protein were examined by western blotting in control and PDHA1-KO LnCap cells. From [1].
Antibody information

Rabbit monoclonal IgG

Company: Cell Signaling

Antibody: Pyruvate Dehydrogenase

Catalog number: 3205

Summary: Rabbit monoclonal IgG against a synthetic peptide corresponding to the sequence of human pyruvate dehydrogenase. Reacts with human, mouse, rat and monkey. Suitable for western blot and immunohistochemistry (paraffin).

Validation Method

Western blot

Sample

Control and PDHA1-KO LnCap cells. Cells subjected for Western blotting were homogenized using RIPA buffer (Thermo Scientific Pierce Company).

Blocking agent

5% milk.

Secondary incubation

Horseradish peroxidase-conjugated (HRP) antibodies.

Detection

Enhanced chemiluminescence (Amersham, Arlington Heights, IL) and exposed to X-ray film.

References
  1. Zhong Y, Li X, Ji Y, Li X, Li Y, Yu D, et al. Pyruvate dehydrogenase expression is negatively associated with cell stemness and worse clinical outcome in prostate cancers. Oncotarget. 2017;: pubmed publisher